TO THE EDITOR
Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) is a myeloproliferative disorder, characterized by the t(9;22)(q34;q11) translocation, originating in a multipotent hematopoietic stem cell. Imatinib mesylate is a tyrosine kinase inhibitor that has been shown to block growth and induce apoptosis in BCR-ABL-expressing hematopoietic cells. 1 It can also inhibit the activity of other tyrosine kinases including KIT and platelet-derived growth factor receptor (PDGFR). 2 Most of the patients under imatinib achieve a major or complete cytogenetic remission (less than 35% of Ph þ metaphases in the bone marrow), with restoration of a Philadelphia-negative hematopoiesis. 3 However, almost one-third of the patients have thrombocytopenia and neutropenia as a consequence of their treatment. 3 Recently, some reports on the emergence of clonal chromosomal abnormalities in the Ph-negative cells of CML patients under imatinib treatment have appeared in the literature. [4] [5] [6] [7] [8] [9] [10] [11] [12] In all, 46 CML patients are presently under imatinib at both institutions, most of them because of resistance or intolerance to interferon alfa. Conventional cytogenetic studies of bone marrow cells, using a 24-h culture synchronized with FudR, were performed at diagnosis, before starting imatinib, and at 3-6-month intervals during treatment. 13 A patient was said to have a complete cytogenetic response (CCR) when no Ph-positive metaphase was found among the 20 observed in conventional cytogenetics. A major cytogenetic response (MCR) was achieved when the proportion of Phpositive metaphases was included between 1 and 34%, a partial cytogenetic response between 35 and 65%, a minor cytogenetic response between 66 and 95%, and no cytogenetic response when the frequency of Ph-positive metaphases was higher than 95%.
Interphase fluorescent in situ hybridization (I-FISH) was performed on the bone marrow samples using LSI bcr/abl dual ES color (Vysis, Voisins le Bretonneux, France), as previously described. 13 At least 300 interphase cells were scored for signal patterns. The analysis was completed using appropriate centromeric probes, depending upon the results of conventional cytogenetics.
Cytogenetic studies were sequentially performed on 46 CML patients receiving imatinib. Six (13%) had no cytogenetic response, four (8.7%) a minor cytogenetic response, one (2.2%) a partial cytogenetic response, six (13%) a major cytogenetic response, and 29 (63%) a complete cytogenetic response.
Among those 29 patients achieving a complete cytogenetic response, three (10.3%) developed clonal chromosomal abnormalities in the Ph-negative cells ( The third patient received hydroxyurea following the diagnosis of chronic myeloid leukemia in June 2001 to reduce his white blood cells (WBC) count. He was then put under imatinib (400 mg/day) and aracytidine (40 mg/day, 14 days a month), without having been treated with interferon alfa. The dosage of aracytidine had to be reduced because of thrombocytopenia and neutropenia, before being stopped after 6 months. At 8 months of treatment, neutropenia (WBC 3.1 Â 10 9 /l with 17% neutrophils) and thrombocytopenia (platelets 86 Â 10 9 /l) persisted. The conventional cytogenetic analysis at 10 months under imatinib showed the disappearance of the Philadelphia chromosome in all 21 metaphases examined; a monosomy 7, confirmed by interphase FISH, was found in 19 metaphases. The patient has remained under imatinib (400 mg/day). When last seen 22 months after imatinib was started, he was still bicytopenic (WBC 2.5 Â 10 9 /l with 19% neutrophils and platelets 74 Â 10 9 /l); the monosomy 7 was still present in 13 of the 21 metaphases analysed.
In all the three patients, the BCR-ABL fusion gene signal was absent in all 300 cells examined by interphase FISH at the time the other chromosomal abnormalities appeared. Interphase FISH performed retrospectively on all three patients showed the absence of nullisomy Y or monosomy 7 in the samples taken prior to imatinib treatment.
This report documents the emergence of clonal chromosomal abnormalities in Philadelphia-negative cells of three CML patients under imatinib achieving a complete cytogenetic response, as reported by other workers. At present, data on 1584 patients are available. Among the 49 patients with an abnormal Philadelphia-negative clone, 43 had achieved a MCR or CCR at the time the clone appeared. There is no doubt that patients responding very well at the imatinib treatment are at a higher risk of developing cytogenetic abnormalities in the Phnegative cells. The frequency of patients developing clonal chromosomal abnormalities in their Ph chromosome-negative cells remain unknown because large trials of imatinib treatment usually do not report them, while studies dedicated to their emergence induce a bias toward reporting them.
Overall, 60 patients with an abnormal Philadelphia-negative clone have been published thus far, including 49 patients reported in series and 11 as case reports; 34 (56.7%) had a trisomy 8, 11 (18.3%) a monosomy or deletion of the long arm of chromosome 7, five (8.1%) a deletion of the long arm of chromosome 20, and four each (6.5%) a monosomy or deletion of the long arm of chromosome 5 or nullisomy Y. In a few patients, two independent abnormal cell lines were identified; three patients had a þ 8 and a -7 clone.
6,9 Also, sometimes, the clonal abnormalities were identified only once during follow-up. 12 Two of our patients became nullisomic Y during imatinib treatment. They were 72 and 73 years old when imatinib was started. Two cases have been previously reported in a 56-and a 70-year-old male.
11 Loss of the Y chromosome in bone marrow cells is known to be an age-related phenomenon. It is also found in males with myelodysplastic syndrome (MDS) or acute nonlymphocytic leukemia. All the four males with nullisomy Y are older patients. Therefore, this finding could be attributed to age, but it has not be seen in patients treated with interferon alfa.
9,11
Almost one-third of the patients have thrombocytopenia and neutropenia as a consequence of their treatment. 3 Most of the clonal chromosomal abnormalities ( þ 8, À7, 7qÀ, À5, 5qÀ, 20qÀ) found in Ph-negative cells are also seen in myelodysplastic syndromes. These patients usually showed varying degrees of dysplastic morphologic changes. However, no apparent correlation exists between the presence of karyotypic aberrations and the mild myelodysplastic features observed in these patients, since the latter are also observed in patients under imatinib without chromosomal abnormalities. 5 Several hypotheses have been put forward to explain the emergence of these abnormal Ph-negative clones.
5,9-11 They are apparently not related to the development of de novo acute leukemia; indeed, it is difficult to understand why treatment with imatinib would trigger acute leukemia in so many patients and in a short period of time. Secondary myelodysplastic syndromes or acute leukemias are also unlikely because some patients did not receive, or only for a short period, chemotherapy known to induce treatment-related hemopathies. It was also hypothesized that the abnormal Ph-negative clones predated the onset of CML, but were undetected because Ph-positive cells populated the marrow due to their proliferative advantage. However, in our cases, no nullisomy Y or monosomy 7 was found before imatinib treatment was started.
Lastly, the emergence of new clonal chromosomal abnormalities could be due to some secondary effects of imatinib. Imatinib, by its tyrosine kinase-inhibiting action, affects important hematopoietic growth-regulatory proteins such as PDGFR, ABL, and KIT. 2 Following the depression of the proliferation of the Ph-positive progenitor cells by imatinib, the Ph-negative stem cells start proliferating again, may be in a dysregulated manner. Still, the significance of these Ph-negative cytogenetically abnormal clones remains unknown.
In conclusion, CML patients treated with imatinib should be regularly monitored with conventional cytogenetic techniques, not only to follow the decrease in the proportion of Ph-positive cells, but also to look for new Ph-negative clonal chromosomal abnormalities. Juvenile myelomonocytic leukemia (JMML) is a clonal myeloproliferative disorder seen in young children and is characterized by leukocytosis with monocytosis, thrombocytopenia, hepatosplenomegaly, and elevated fetal hemoglobin caused by a reversion to fetal-like erythropoiesis. 1 The Ras signaling pathway is known to be deregulated by mutations in the RAS gene or the neurofibromatosis type 1 gene (NF1) in approximately 40% of JMML cases.
The PTPN11 gene, which encodes the nonreceptor protein tyrosine phosphatase SHP-2, has recently been shown to play a crucial role in the pathogenesis of JMML: SHP-2 acts as an upstream regulator of RAS, and somatic PTPN11 mutations were found in 34% of JMML patients without Noonan syndrome. 2 Germline PTPN11 mutations are known to lead to Noonan syndrome, a multiple malformation syndrome characterized by unique facial features, neck webbing, and pulmonic stenosis. A subset of patients with Noonan syndrome also develop JMML.
Currently, the level of hematopoietic differentiation at which somatic PTPN11 mutations arise in JMML patients remains unknown. In the present study, we performed a PTPN11 mutation analysis of leukemic marrow cells, Epstein-Barr virus (EBV)-transformed B lymphocytes, IL-2-stimulated peripheral blood (PB) cells, and buccal smear cells from two JMML patients without Noonan syndrome to document possible hematopoietic lineage-dependent genomic alterations at the PTPN11 locus.
Both patients reported here had neither the features nor a family history of neurofibromatosis type 1 or Noonan syndrome. The study protocol was approved by the Ethics Committee of Keio University's School of Medicine and the National Cancer Center. After obtaining informed consent from the patients' parents, the patients' leukemic marrow cells were screened for PTPN11 mutations. Genomic DNA was isolated using a desalting column (Qiagen, Chattsworth, CA, USA). Exon 3 and exon 8 in PTPN11, known to be mutation hot spots, 2 were analyzed by direct sequencing of the PCR products amplified from the genomic DNA using a previously described method. 3 To obtain T lymphocytes for the mutation analysis, PB cells were cultured and expanded using a TLY Culture kit25 (Lymphotec, Tokyo, Japan), which comprises plastic flasks coated with anti-CD3 monoclonal antibody and RPMI-1640 medium containing 10% fetal calf serum and IL-2, as described previously. 4 Almost all the IL-2-stimulated PB cells cultured by this method have been shown to be CD3-positive lymphocytes. 4 To prevent contamination of DNA derived from myeloid cells, high molecular weight DNA was isolated from the IL-2-stimulated PB cells after culture for 3 weeks according to standard protocols.
Patient 1: A 2-year-old boy presented with marked hepatosplenomegaly, skin lesions, thrombocytopenia (25.0 Â 10 9 /l), and leukocytosis (26.8 Â 10 9 /l) with myeloid precursors and a monocyte percentage of 16.5%. A bone marrow aspirate revealed granulocytic hyperplasia consisting of less than 5% blasts and a normal karyotype (46,XY). An elevated fetal hemoglobin level (50%) and a decreased neutrophil alkaline phosphatase (NAP) score of 29 were consistent with a diagnosis of JMML. Analysis of the genomic DNA derived from the leukemic bone marrow aspirate revealed an A4C transition in exon 3 at nucleotide 227, leading to an E76A substitution. The E76A substitution mutation was not present in an ethnically matched healthy control population of 100 subjects. Furthermore, the E76A substitution mutation was not found in the patient's EBVtransformed B lymphocytes ( Table 1 ). The patient was treated with 6-mercaptopurine (6-MP). At 4 months after the diagnosis of JMML, the patient underwent allogeneic bone marrow transplantation (allo-BMT) from an HLA-identical sibling.
Patient 2: A 4-month-old boy presented with progressive hepatosplenomegaly, thrombocytopenia (71.0 Â 10 9 /l), and leukocytosis (49.8 Â 10 9 /l) with myeloid precursors and a monocyte percentage of 25.5%. A bone marrow aspirate revealed marked granulocytic hyperplasia consisting of less than 5% blasts and a normal karyotype (46,XY). A mildly elevated fetal hemoglobin level (3.6%) and a decreased NAP score of 75 were
